Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas S Downing

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Safety|December 8, 2017
New and incremental FDA black box warnings from 2008 to 2015Michael T Solotke, Sanket S Dhruva, Nicholas S Downing, et al.
JAMA|July 29, 2015
Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013Harlan M Krumholz, Sudhakar V Nuti, Nicholas S Downing, et al.
BMJ Open|January 6, 2016
Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilotJiapeng Lu, Si Xuan, Nicholas S Downing, et al.
JAMA Network Open|June 10, 2021
Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019Meera Dhodapkar, Audrey D Zhang, Jeremy Puthumana, et al.
JAMA Network Open|April 22, 2020
Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017Audrey D Zhang, Jeremy Puthumana, Nicholas S Downing, et al.
International Journal of Cancer|September 21, 2017
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional studyJean-David Zeitoun, Gabriel Baron, Alexandre Vivot, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 25, 2017
Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014Vinay K Rathi, Bo Wang, Joseph S Ross, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 18, 2017
Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014Vinay K Rathi, Bo Wang, Joseph S Ross, et al.
BMJ Open|December 24, 2017
Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional studyJean-David Zeitoun, Joseph S Ross, Ignacio Atal, et al.
Clinical Pharmacology and Therapeutics|January 30, 2018
Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable AnalysisJean-David Zeitoun, Joseph S Ross, Ignacio Atal, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Safety|December 8, 2017
New and incremental FDA black box warnings from 2008 to 2015Michael T Solotke, Sanket S Dhruva, Nicholas S Downing, et al.
JAMA|July 29, 2015
Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013Harlan M Krumholz, Sudhakar V Nuti, Nicholas S Downing, et al.
BMJ Open|January 6, 2016
Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilotJiapeng Lu, Si Xuan, Nicholas S Downing, et al.
JAMA Network Open|June 10, 2021
Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019Meera Dhodapkar, Audrey D Zhang, Jeremy Puthumana, et al.
JAMA Network Open|April 22, 2020
Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017Audrey D Zhang, Jeremy Puthumana, Nicholas S Downing, et al.
International Journal of Cancer|September 21, 2017
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional studyJean-David Zeitoun, Gabriel Baron, Alexandre Vivot, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 25, 2017
Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014Vinay K Rathi, Bo Wang, Joseph S Ross, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 18, 2017
Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014Vinay K Rathi, Bo Wang, Joseph S Ross, et al.
BMJ Open|December 24, 2017
Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional studyJean-David Zeitoun, Joseph S Ross, Ignacio Atal, et al.
Clinical Pharmacology and Therapeutics|January 30, 2018
Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable AnalysisJean-David Zeitoun, Joseph S Ross, Ignacio Atal, et al.
Pageof 5